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Abstract 
Cardiac safety assessments are commonly employed in the clinical development of investigational oncology medications. In anti-cancer 
drug development there has been increasing consideration for the potential of a compound to cause adverse electrocardiographic 
changes, especially QT interval prolongation, which can be associated with risk of torsades de pointes and sudden death. Irrespective of 
overt clinical toxicities, QTc assessment can potentially influence decision making at many levels during the conduct of clinical studies, 
including eligibility for protocol therapy, dose delivery or discontinuation, and analyses of optimal dose for subsequent development. 
Given the potential for serious and irreversible morbidity from cardiac adverse events, it is understandable that cardiac safety results can 
have broad impact on study conduct and patient management. The methodologies for risk management of QTc prolongation for non 
cardiac drugs have been developed out of experiences primarily from drugs used to treat non life-threatening illnesses in a chronic 
setting such as antibiotics or antihistamines. Extrapolating these approaches to drugs for treating cancer over an acute period may not 
be appropriate. Few specific guidelines are available for risk management of cardiac safety in the development and use of oncology 
drugs. In this manuscript, clinical and methodological issues related to QTc prolongation assessment will be reviewed. Discussions about 
limitations in phase-I design and oncology drug development will be highlighted. Efforts are needed to refine strategies for risk 
management, avoiding unintended consequences that negatively affect patient access and clinical development of promising new cancer 
treatments. A thoughtful risk management plan generated by an organized collaboration between oncologists, cardiologists, and 
regulatory agencies to support a development programme essential for oncology agents with cardiac safety concerns.
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Introduction 
Prolongation of the QT interval associated with the potential 
fatal arrhythmia known as ‘torsades de pointes’ (TdP) has been 
a common cause of withdrawal from the market for several 
drugs [1]. Clinical trial designs have been well described to 
identify and quantify QTc prolongation. In the absence of other 
completely reliable surrogate measure for the arrhythmogenic 
potential of a drug, the characterization of QT interval 
prolongation is now considered essential for most new drug-
development programmes. The decision in oncology by a 
patient to receive, or by a physician to administer, a promising 
anti-cancer agent (or by a regulatory agency to approve one) is 
predicated on the assumption that the benefits of therapy 
outweigh the risks. Thus, although clinicians, members of 
regulatory bodies and drug developers may be able to predict 
that a given drug may carry some risks due to QTc 
prolongation, precise determination of relative risk vs benefit 
remains elusive for the development and application of many 
anti-cancer agents. In this review, we summarize recent 
experience in oncology regarding clinical predictors of drug-
induced prolongation of the QT interval and torsades de 
pointes, consider how new molecular predictors of a drug's 
activity might be incorporated into anti-cancer drug-
development programmes and clinical practice, and suggest a 
general approach to drugs that are suspected of causing this 
problem. 
 
Historical background 
TdP was first described in 1966 by the French cardiologist 
Dessertenne [2]. Until 1989, TdP was known to occur fairly 
frequently during the initiation of class III anti-arrhythmic drugs 
(so that patients were placed on telemetry during the initiation of 
such drugs), fairly rarely in patients receiving psychiatric drugs 
(so that nothing systematic was done for these patients) and 
occasionally in very sick hospitalized patients receiving 
intravenous erythromycin. In the fall of 1989, the first recognized 
case of QTc prolongation and TdP associated with terfenadine 
was described by physicians at the National Naval Medical 
Center in Bethesda, Maryland [3]. This was a landmark adverse 
drug reaction that triggered the awareness that many apparently 
benign non-cardiovascular drugs could occasionally have the 
unwanted ability to prolong cardiac repolarization and thus 
contribute to torsades de pointes in susceptible patients. In the 
process of elucidating the mechanism of terfenadine-associated 
QT prolongation and TdP, it was demonstrated that terfenadine, 
but not its active metabolite fexofenadine, had the unanticipated 
property of blocking IKr and thus prolonging the QT interval [4]. 
The first regulatory document addressing the evaluation of non-
cardiovascular drugs to alter cardiac repolarization in humans 
was published in 1997 [5]. Subsequently, the Food and Drug 
Administration (FDA) and the International Conference on 
Harmonization (ICH) followed suit with the E14 guidance 
document entitled ‘The Clinical Evaluation of QT/QTc Interval 
Prolongation and Proarrhythmic Potential for Non-
Antiarrhythmic Drugs’, that was accepted in 2005 [6]. In addition 
to traditional drug products, recent experiences have raised 
concerns about direct or indirect actions to prolong QTc and/or 
to induce arrhythmia by other agents, including biologics and 
hormones. 
 
Clinical Background 
Multiple factors have been implicated in causing QT 
prolongation and TdP. Among these, improper use of QT-
interval-prolonging medications deserves special attention [7,8]. 
To reduce the risk of torsades de pointes, clinicians from all 
therapeutic areas should understand the fundamentals of drug-
induced QTc prolongation. Another issue is related to congenital 
syndromes involving QT-interval prolongation. A convergence of 
data obtained from clinicians, basic electrophysiologists, and 
geneticists have improved understanding of the mechanisms 
whereby drugs may cause this type of arrhythmia. Although it is 
convenient to think of QT prolongation as occurring because of 
either congenital or acquired abnormalities, the phenomenon 
may sometimes involve a gene–environment interaction. Pure 
congenital prolongation characterized by lifelong, ambient QT 
prolongation is rare but does carry a high risk of sudden death. 
Several forms of congenital LQTS have been reported, and 
three forms (LQT1, LQT2, and LQT3) have been well 
characterized in previous studies [9–11] (Table 1). 
 
What is the QT interval? 
The QT interval on the surface ECG is measured from the 
beginning of the QRS complex to the end of the T wave (Figure 
1). It is the electrocardiographic manifestation of ventricular 
depolarization and repolarization. This electrical activity of the 
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Table 1: LQT syndromess 
 
 
Figure 1: ECG representation and QT interval
heart is mediated through channels, complex molecular 
structures within the myocardial cell membrane that regulate the 
flow of ions in and out of cardiac cells. The rapid inflow of 
positively charged ions (sodium and calcium) results in normal 
myocardial depolarization. When this inflow is exceeded by 
outflow of potassium ions, myocardial repolarization occurs. 
Malfunction of ion channels, which can result from drugs, 
electrolyte abnormalities, or other factors, leads to an 
intracellular excess of positively charged ions by way of an 
inadequate outflow of potassium ions or excess inflow of 
sodium ions. This intracellular excess of positively charged ions 
extends ventricular repolarization and results in QT-interval 
prolongation [12]. 
Basic electrophysiological and genetic 
background 
The ventricular action potential proceeds through five phases. 
The initial upstroke (phase 0—depolarization) occurs through 
the opening and closing of Na+ channels. The repolarization 
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process begins with the rapid transient outflow of K+ ions 
(phase 1). This is followed by the flow of outward current 
through two delayed rectifier K+ channels (IKs, IKr) and of 
inward current through Ca2++ channels, constituting phase 2 or 
the plateau phase of repolarization. Increasing conductance of 
the rapid delayed rectifier (IKr) and inward rectifier (IK1) 
currents completes repolarization (phase 3). Phase 4 
represents a return of the action potential to baseline. The LQT1 
gene (also known as KCNQ1 and KvLQT1) encodes voltage-
gated potassium channel alpha subunits. A tetramer of 4 
KCNQ1 alpha subunits co-assembles with the minK gene 
product (beta regulatory subunit) to form the IKs slowly 
deactivating delayed rectifier potassium channel [13]. The 
patients with LQT1 account for about 42% of all patients with 
congenital LQTS [14,15]. The gene for LQT2 (also known as the 
KCNH2 and human ether-a-go-go-related or hERG gene) spans 
55 kb and also encodes potassium channel alpha subunits. In 
terms of electrophysiology, hERG mutations cause potassium 
ion channels to deactivate (close) much faster, blunting the 
normal rise in current (IKr) that results from rapid recovery from 
channel inactivation/slow deactivation [13]. The LQT3 gene, 
SCN5A, encodes alpha subunits which form a fully sodium 
functional channel; beta subunits have a modifying influence. 
The gene responsible for LQT4, 220 kb in length, encodes the 
ankyrin-B (ANKB or ANK2) adaptor-protein. The LQT5 gene 
encodes the KCNE1 protein, which contains a single 
transmembrane spanning domain with small intra and extra-
cellular components. The product of the minK gene forms the 
beta subunit of the LQT1 assembly regulating the IKs potassium 
channel current. The patients with this form of LQTS account for 
about 3% of all patients with LQTS. The LQT6 gene encoding 
MiRP1, or minK-related protein 1, is located 70 kb from minK on 
the same chromosome. The LQT7 genotype has been mapped 
to the inward rectifying potassium channel gene KCNJ2 on 
chromosome 17. The rare form of LQT7 (Andersen Syndrome) 
produces a combination of both a skeletal and cardiac muscle 
phenotype. The most recent addition, LQT8, has been mapped 
to the calcium channel gene CACNA1C on chromosome 12. 
 
Measurement and interpretation of the QT 
Interval 
Because the QT interval is prolonged at slower heart rates and 
shortened at faster heart rates, many formulas have been 
proposed to adjust for these variations (Table 2). Yet 
differences of opinion exist regarding the most useful correction 
for heart rate [16–19]. One of the commonly used formulas is 
the Bazett formula, in which the QT interval is adjusted for heart 
rate by dividing it by the square root of the R–R interval. 
However, this formula has been criticized for being inaccurate at 
fast heart rates [20]. Other formulae are the Fridericia cube-root 
correction (QT interval divided by the cube root of the R–R 
interval) and the Framingham linear regression equation 
[17,18]. From an epidemiological perspective, the Framingham 
approach is supported because it is based on empirical data 
from a large population sample rather than on hypothetical 
reasoning. Analyses of QTc by the Fridericia correction (QTcF) 
has been considered for primary analysis (or co-primary along 
with Bazetts) in studies that are conducted in patients with 
malignancy, especially when increased heart rates are generally 
observed. Unfortunately, none of these corrections has been 
examined comparatively to determine the most effective formula 
in predicting which patients are at greatest risk of TdP. 
Factors that affect the QT interval 
Although it is convenient to think of QT prolongation as 
occurring because of either congenital or acquired 
abnormalities, the phenomenon probably most often involves a 
gene–environment interaction. Pure congenital prolongation 
characterized by lifelong, ambient QT prolongation is rare but 
does carry a high risk of sudden death [21–27]. When exposed 
to QT-prolonging medications, individuals without lifelong QT 
prolongation may develop QT prolongation with or without TdP 
or may not develop QT prolongation at all. Even after 
adjustment for other factors that could prolong QT interval, 
some patients seem to be more likely than others to have QT 
prolongation at a given dose of a drug. This observation led 
researchers to hypothesize that patients with acquired QT 
prolongation may have a genetic predisposition for it. Recent 
investigations suggest that such patients may have clinically 
silent gene mutations that lead to overt QT prolongation only 
with exposure to QT-prolonging medications [12, 26, 27]. It is 
important to note that the majority of patients with documented 
acquired LQTS never experience TdP, and many patients with 
TdP have a normal QT interval shortly before the event. It 
appears that a variety of coincident circumstances, including 
genetic predisposition and a prolonged QT interval, are required 
to precipitate TdP. Factors that predispose to QT prolongation 
and higher risk of TdP include older age, female sex, low left 
ventricular ejection fraction, left ventricular hypertrophy, 
ischemia, slow heart rate, and electrolyte abnormalities 
including hypokalemia and hypomagnesemia [28–36]. A 
complete summary of factors affecting QT interval is reported in 
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Table 2: QT correction formulae 
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Table 3: Risk Factors for torsade de pointes 
Table 3. Regarding antiarrhythmic QT-prolonging drugs, the risk 
of TdP seems to be highest within the first few days of starting 
therapy [37–40]. For this reason, physicians consider 
compulsive ECG monitoring at the initiation of treatment, 
including hospitalization that may be especially warranted in 
patients with established risk factors, since hospitalized patients 
can be better monitored for the warning signs that precede TdP. 
Tables 4 and 5, respectively, report drugs related to QTc 
prolongation and underlying molecular mechanisms. 
 
Correlation of QT prolongation with TdP or 
other clinically significant events 
QT prolongation is a surrogate marker for the risk of developing 
TdP or other life-threatening arrhythmias. While there is a 
general qualitative correlation between QTc and risk for TdP, it 
is not possible to make a quantitative prediction for the risk of 
TdP for a given QTc prolongation. Thus while it makes sense 
not to accept a very small risk of TdP for a drug like terfenadine 
or cisapride, it is more difficult to know what degree of QTc 
prolongation would lead to such a large risk of TdP so as to 
make an anti-cancer drug unacceptable. One can measure the 
efficacy parameters in clinical trials, but regarding the risk for 
QTc, no study has made a quantitative assessment looking at 
any medication in the oncology setting. This is particularly 
difficult to assess because many cancer patients have many 
other factors that may increase their risk of arrhythmias 
including medication, cardiac disease, drug-induced heart injury 
and electrolyte abnormalities. The association of QT 
prolongation with arrhythmias can be influenced by a variety of 
factors mentioned in the previous section but can also be drug 
specific. For example, amiodarone can significantly prolong 
QTc, but it appears to cause only rare cases of TdP. 
 
QTc prolongation and anti-cancer drugs 
The decision by a physician to use a drug is predicated on the 
assumption that the benefits of therapy, however defined, 
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Table 4: Drug inducing QTc prolongation 
 
 
Table 5: Ion channels and QT prolonging drugs 
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outweigh the risks, however measured. For a cancer patient, 
the possibility of a cure for the cancer may outweigh the 
potential risks of QTc prolongation, even when the prolongation 
is high. 
Arsenic trioxide
Arsenic trioxide (ATO) presents an interesting example of 
successful risk management, supporting the decision for a 
patient to accept, or a physician to administer an anti-cancer 
drug with established liabilities of QTc prolongation and TdP. 
Although this drug is known to provoke TdP [41] it is also 
uniquely effective in an otherwise fatal disease, relapsed acute 
promyelocytic leukaemia (APL) [42]. Therefore, until alternative 
therapy becomes available, arsenic trioxide remains a drug of 
choice, despite its potential for causing arrhythmia. In patients 
receiving multiple courses, QTc intervals may return to pre-
treatment levels before the second course, signifying that serial 
ATO administration does not permanently prolong the QTc 
interval; however, documented episodes of TdP have been 
diagnosed beyond the first month of treatment, presumed due 
to drug accumulation in cardiac tissue [48]. Given appropriate 
ECG monitoring, identification of contributory factors, and 
management of electrolytes and concomitant medications, ATO 
can be safely administered [45, 48]. Two studies have 
demonstrated the efficacy of ATO in patients with relapsed 
acute promyelocytic leukaemia [43, 44]. In the first study 
patients experiencing first or two or more relapses were treated 
with daily ATO infusions to a maximum of 60 doses or until all 
leukemic cells in the bone marrow were eliminated. Thirty-four 
patients (85%) achieved a complete response. QTc 
prolongation was common (63%). The authors concluded that 
ATO provides important overall clinical benefit for patients with 
relapsed APL. However, cardiac toxicity occurs during ATO 
therapy, and patients should be monitored for prolonged QT 
intervals and ventricular arrhythmia [41,45–49]. Prolonged QT 
intervals developed in 38 patients (26 patients had intervals 500 
milliseconds). All standard ECG tracings (25 mm/sec, 10 
mm/m2) that had been obtained at baseline and during and 
following treatment with arsenic trioxide were collected and sent 
to a central core laboratory for review in a blind test by a single 
board-certified cardiac electrophysiologist. Baseline ECG 
abnormalities were observed in 36 patients, including marked 
sinus tachycardia, bundle branch block, ST-T wave changes, 
atrial fibrillation, and evidence of previous myocardial infarction. 
Despite these abnormalities, in 949 (80%) of the ECGs, the RR 
and QT intervals could be determined, and QTc intervals could 
be calculated. Compared with baseline, the heart rate-corrected 
(QTc) interval was prolonged by 30–60 msec in 36.6% of 
treatment courses, and by more than 60 msec in 35.4% of 
patients. The degree of prolongation was higher in men than in 
women during the first course of therapy, and in patients with 
hypokalemia. In patients receiving multiple courses, QTc 
intervals returned to pretreatment levels before the second 
course, signifying that arsenic trioxide does not permanently 
prolong the QTc interval [41]. In the early APL studies, the 
degree of QTc prolongation was higher in men than in women, 
and in patients with hypokalemia. One patient with relapsed 
APL with hypokalemia during arsenic trioxide treatment 
developed asymptomatic TdP, which resolved spontaneously 
and did not recur after electrolyte replacement [41, 45–47]. The 
risk for TdP has been associated with the magnitude of QTc 
prolongation, pre-existing QTc prolongation, a prior history of 
TdP, and congestive heart failure. One patient with APL 
developed this arrhythmia coincident with amphotericin 
administration, and the risk of TdP has been associated with 
concomitant QT-prolonging drugs. In addition to the potential for 
additive effects by drugs that are also known to prolong QTc, 
concomitant drugs can increase risk by other mechanisms, 
including: (a) drug–drug interaction that increases exposure of 
either agent to concentrations that have more significant effect 
on repolarization; and (b) electrolyte abnormalities. It has been 
demonstrated that ATO prolongs the action potential of guinea 
pig ventricular myocytes via two independent molecular 
mechanisms. ATO increases cardiac calcium currents, which 
regulate the plateau phase of the cardiac action potential but 
also reduces surface expression of the cardiac potassium 
current hERG/IKr, which is crucial to later stages of cardiac 
repolarization [50]. Enhanced outward currents and accelerated 
deactivation kinetics have been reported as a hallmark of hERG 
modulation by radical reactive oxygen species (ROS) [51,52] 
and are compatible with the well-documented property of ATO 
to induce oxidative stress by increasing ROS. 
Anthracycline based regimens
A prospective study [53] was designed to assess the effect of 
epirubicin-based chemotherapy on QT interval prolongation in 
patients with aggressive non-Hodgkin lymphoma, and potential 
impact of co-treatment by the cardioprotective agent 
dexrazoxane. Twenty untreated patients eligible for epirubicin-
based chemotherapy were randomized to receive or not 
dexrazoxane hydrochloride after epirubicin infusion. Twelve-
lead ECGs were recorded before and after epirubicin infusion 
and after dexrazoxane supplementation. All patients showed 
some QTc prolongation after chemotherapy infusion, but these 
effects were significantly reduced in the ten patients who also 
received dexrazoxane. The authors concluded that epirubicin-
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based chemotherapy causes an early increase of the QT and 
QTc prolongation, which is attenuated by dexrazoxane 
supplementation, and so dexrazoxane can hypothetically 
reduce the risk of arrhythmia in patients treated with epirubicin. 
In a previous prospective study, a Finnish group [54] 
investigated the effects of doxorubicin therapy on cardiac 
electrophysiology, with special emphasis on QT prolongation, in 
lymphoma patients who received doxorubicin to a cumulative 
dose of 400–500 mg/m2. Standard 12-lead ECG and signal-
averaged ECG recordings were performed at baseline and after 
cumulative doxorubicin doses of 200, 400 and 500 mg/m2. Five 
patients (18%) developed QT prolongation exceeding 50 msec. 
The changes in QTc occurred independently of the impairment 
of left ventricular function. In children who received 
anthracyclines and thoracic irradiation, analysis of the 12-lead 
and 24-hour electrocardiograms demonstrated increased 
frequency of QTc prolongation, supraventricular premature 
complexes, supraventricular tachycardia, ventricular premature 
complexes, couplets and ventricular tachycardia when 
compared with an age-matched healthy population [55]. 
Tamoxifen
Preclinical and clinical data demonstrated that tamoxifen can 
cause prolongation of the electrocardiographic QT interval in 
humans [56]. The electrophysiological mechanism(s) underlying 
the tamoxifen action are related to blocking the rectifier 
potassium current (IKr) 
Supportive care drugs
The anti-emetic efficacy of serotonin-type-3 (5-HT(3)) receptor 
antagonists has been found to be superior to older anti-emetic 
drugs in many clinical settings. Following the administration of 
these agents, changes in ECG parameters and increased or 
decreased heart rates have been demonstrated [57–59], but 
insufficient data are available that characterize the effects of 
newer anti-emetics on QTc in children or adults in the clinical 
treatment setting for advanced malignancy. The effect of 
droperidol on prolonging QT interval has been well described 
[59]. Some data suggest relatively modest QTc prolongation 
after administration of ondanestron or similar anti-emetics and 
lack of evidence for associated arrhythmias [57,59].However, 
methodological issues from published studies limit firm 
conclusions about the liability QTc from 5-HT(3) receptor 
antagonists, and the published results may not represent the 
effects expected from higher doses often used to manage 
chemotherapy-induced nausea and vomiting, so more clinical 
research is needed given the broad applications in many 
oncology treatment settings. 
  
QTc prolongation and anti-cancer drugs 
development 
Regulatory and methodological issues
New drugs present a special problem, because at the time of 
approval by the FDA or European Medicines Agency (EMEA), 
clinical experience with each drug is limited. Many new agents 
may weakly antagonize IKr or produce a small degree of QT-
interval prolongation but there may be limited rigorous data at 
the high doses that are likely to be given to some patients post-
approval. The decision to develop and approve an anti-cancer 
agent with QTc liability ultimately rests on an estimate of the 
perceived risk relative to the expected benefits for patients and 
society. Estimates of benefit are specific to particular 
indications, but they may include an assessment of whether the 
specific disease entity itself is associated with morbidity or 
mortality, the expected favourable impact of a new treatment, 
and consideration of efficacy and toxicity of other available 
therapies. 
Clinical trial evaluation ‘thorough QT/QTc study’
FDA and EMEA regulatory guidelines advocate that most new 
agents, administered systemically, should undergo an 
electrocardiographic evaluation, beginning early in clinical 
development, typically including a single trial dedicated to 
evaluating their effect on cardiac repolarization (‘thorough 
QT/QTc study’ or TQTS) [60]. Common conventions for 
conducting TQTS include digital data collection with rigorous 
methodology, appropriate rate corrections, categorical analysis 
(outlier), central tendency analysis and pharmacokinetic and 
pharmacodynamic analysis to enable analyses of exposure–
effect relationships. The ability of a drug to prolong the QT/QTc 
interval is linked to pharmacologic effects that can be 
investigated in non-clinical models as well as clinically. At 
present, controversy exists about whether non-clinical testing 
can exclude a clinical risk of QT/QTc prolongation. TQTS would 
be needed in almost all cases when non-clinical data are not 
considered able to preclude the risk of QT/QTc prolongation. 
Additional factors that could influence the need for such a study 
include duration of treatment, metabolic profile, 
pharmacodynamic duration of action, and previous experience 
with other members of the same chemical or pharmacological 
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class. At least two approaches can be described that 
correspond to different drug categories: (1) the TQTS for most 
drugs, and (2) the cardiology safety assessment often 
conducted as an ancillary sub-study in a phase-dose-escalation 
trial for cytotoxic or neuroleptic drugs (which could not be tested 
in healthy volunteers). The TQTS is a well-controlled double-
blind study conducted in healthy volunteers. Commonly, a 
'crossover' study design is employed where the ECG data are 
collected in the same patients before and during the treatment 
(drug-off and drug-on). For the drugs with a long half-life or with 
active metabolites and/or for schedules consisting of multiple 
doses, a ‘parallel group’ design can be employed. The positive 
control (whether pharmacological or non-pharmacological) 
should be well characterized and should consistently produce 
an effect corresponding to the largest change in the QT/QTc 
interval that is currently viewed as clinically not important. 
Studies should characterize the effect of a drug on the QT/QTc 
throughout the dosing interval. While the peak serum 
concentration does not always correspond to the peak effect on 
QT/QTc interval, care should be taken to perform ECG 
recordings at time points around the measured Cmax (maximal 
concentration). According to regulatory guidance about 
characterization of QTc prolongation in the early development of 
new therapeutic agents, until the effects of the drug on the 
QT/QTc interval have been characterized the following 
exclusion criteria are suggested: (1) a marked baseline 
prolongation of QT/QTc interval (e.g. repeated demonstration of 
a QTc interval >450); (2) a history of additional risk factors for 
TdP (e.g. heart failure, hypokalemia, family history of Long QT 
Syndrome); (3) the use of concomitant medications that prolong 
the QT/QTc interval. Regarding the development of oncology 
products, discussions continue between regulators and other 
stakeholders about the timing of QTc studies in early vs late 
development, and the applications of these exclusion criteria. 
The results of the TQTS will influence the amount of information 
collected in later stages of development: (a) a negative TQTS, 
even in the presence of non-clinical data of concern, will almost 
always allow the collection of on-therapy ECGs in accordance 
with the current practices in each therapeutic area to constitute 
sufficient evaluation during subsequent stages of drug 
development; (b) a positive TQTS will almost always call for an 
expanded ECG safety evaluation during later stages of drug 
development. For development of anti-cancer and other special 
agents, clinical protocol designs to characterize QTc 
prolongation remains an area of active research and discussion 
among regulators and the pharmaceutical industry. The TQTS 
design is not readily applicable to cytotoxics or other oncologics, 
especially the agents that cannot be administered to healthy
volunteers at therapeutic or super-therapeutic exposures. 
Cardiac safety is often evaluated in phase-I studies, conducted 
in patients with advanced malignancy. Clearly, oncology phase-I 
studies are not commonly randomized (crossover or parallel) 
with placebo groups, and they often lack the internal controls 
and eligibility requirements used in the TQTS. There are no 
specific rules in the E14 (ICH guidelines) which apply for special 
drugs such as those in  oncology. E14 specifically recognizes 
that the ‘thorough study’ cannot be performed with cytotoxic 
drugs in healthy volunteers. The E14 only states ‘other ways of 
detecting effects on the QT/QTc interval need to be developed. 
These might include the collection of ECGs at multiple time 
points under tightly controlled settings that target a broad range 
of doses early in development’. 
 
QTc prolongation in oncology drug 
development plans 
When one is prepared to take a drug into clinical development 
for a specific oncology indication, a clinical development plan 
must consider the degree of risk for QT prolongation. If the risk 
is small, based on known class effects and preclinical 
information, then the detailed evaluation of QTc risk can be 
deferred to the phase-II programme (or phase III), and the 
phase-I programme can just have routine surveillance ECGs. If 
the drug has a significant risk of QT prolongation prior to clinical 
trials, then it is important to evaluate that risk in the phase-I 
trials. Whatever the plan, it should have feedback and approval 
in advance from the regulatory agencies at the appropriate 
times. The degree of QT prolongation that is acceptable when 
making a decision if a drug should go into development or 
continue development is highly dependent on commercial, 
medical and regulatory variables that are not easy to integrate. 
While more than a 5 msec increase is not acceptable for some 
drugs, the arsenic trioxide example demonstrates that a drug 
with a much longer increase can have approval. The clinical 
development plan must prospectively take into consideration 
what degree of prolongation would be acceptable, and 
undertake trials that can document the degree of QT 
prolongation that the drug actually causes. In other words, the 
trials must provide the investigators and sponsor the information 
to continue or stop development, to provide the regulatory 
agencies the information they need to approve or disapprove 
the drug, and ultimately provide the physicians the information 
they need to proceed. All of these decisions need specific 
considerations in oncology. 
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Clinical and methodological considerations 
in phase-I oncology trials 
Several levels of concern can be highlighted in designing 
phase-I trials in oncology, that may be different from other 
indications (patient concerns, protocol design issues, and 
regulatory issues). First of all are patient concerns: (1) the 
safety of the patient is of paramount importance. Based on drug 
pharmacokinetics and known preclinical or clinical signals for 
risk of QTc prolongation, an appropriate safety plan for 
monitoring QTc and responding to potential changes must be 
put in place. This can range from periodic ECG data collection 
and reading, that can have a turnaround measured in days for 
oral medications with low risk, to rapid QTc assessments based 
on bedside machine readouts for immediate decisions as to 
possible IV-drug discontinuation for medication with high risk. 
The medical team should have sufficient experience and 
training for an optimal safety assessment and subsequent 
decision-making; (2) patient capabilities and compliance in 
tolerating trial demands must be considered—the timing of the 
ECG is usually concomitant to pharmacokinetic blood sampling 
and requires outstanding compliance from the patient enrolled 
into the study; (3) for drugs with a significant risk of QTc 
prolongation, rapid assessment and decision making during 
administration of the drug can induce psychological distress that 
needs to be mitigated through education and preparation 
including the informed consent process. 
Another level of concern is related to protocol issues. Trial 
protocols described in E14 have many features feasible in 
healthy volunteers or in patients from many therapeutic areas, 
but are not consistent with conventional care of patients with 
advanced malignancy enrolled in oncology trials. Oncology trial 
design issues can be divided into trial design issues and 
technical ECG issues. The trial design issues come from 
defining the purpose of the study and how the potential QT 
evaluation will affect the trial. For example, if there is no known 
QT prolongation risk for the drug, then routine surveillance 
ECGs can be done at baseline, at peak drug concentrations, 
and at a delayed time in case the QT prolongation is related to a 
metabolite of tissue accumulation. Another example would be to 
establish QT prolongation only for what might be life-threatening 
levels (>500 msec) without trying to document small changes. 
The definition of dose-limiting toxicities (DLTs) is important in 
phase I trials. The CTCAEv3 definition of Grade 3 QT 
prolongation is defined as QTc >500 msec without life 
threatening arrhythmias. Definition of clinical trial inclusion 
criteria is another important topic. In two studies, the 
appropriate reference values for adult patients with solid 
tumours, enrolled across various phase-I programmes were 
evaluated [61,62]. Data indicated that the distribution of QTc 
values increased when compared with results from a trial with 
similar ECG methods conducted in healthy volunteers. This 
implies that if exclusion criteria of 450 msec were considered, 
more than 10% of patients from phase-I or phase-II studies 
would be excluded because of marginally prolonged QTc at 
baseline. In view of the major difficulties in conducting a formal 
TQTS for an oncology product, it is not conceivable to exclude 
all patients with prolonged QTc at baseline. Such exclusions are 
often problematic for patients and caregivers, given the 
perceptions that phase-I studies offer access to new agents that 
can provide some opportunity for disease control; that the risk of 
QTc prolongation implies rare or poorly defined relationship to 
significant arrhythmia or other adverse clinical outcome; and of 
the relative risks of alternative treatments or disease 
morbidities. 
Many technical protocol decisions related to the ECGs need to 
be made. These issues can be approached essentially in the 
same way in oncology trials as in trials in any other area, except 
that the special needs of oncology patients must be recognized. 
E14 addresses these technical issues in general ways, and 
more details are provided in other publications [63]. 
Measurement of QTc is highly variable. It is well described that 
measurements taken minutes apart typically differ by up to 40 
msec, variations that do not correlate with known physiological 
differences. Thus important decisions such as eligibility, DLTs, 
drug interruptions, should not be made on single measurements 
but one should average multiple measurements taken minutes 
apart.  
 
 Conclusion 
Clinicians are increasingly faced with both old and new anti-
cancer agents that have the potential to prolong the QT interval; 
a laboratory finding that is associated with the risk of significant 
arrhythmia. As more sensitive methods for electrocardiographic 
testing are applied, an increasing number of anti-cancer agents 
or treatments for supportive care will likely be described with 
some risk for QTc prolongation. For many agents, the frequency 
of QTc prolongation may be common while the risk of clinical 
arrhythmia (TdP) may be very rare. To enable the development 
and application of future treatments, detailed analyses and 
publication about TdP events, observed in cancer treatment 
settings, should continue to support rational strategies for risk 
management with broad relevance. Oncologists have 
demonstrated their ability to identify and manage complicated 
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cardiac risks in clinical investigations and general practice. 
Across multiple geographic regions, successful risk 
management is exemplified by the published experiences with 
arsenic trioxide, highlighting the value of systematic ECG 
testing and attention to concomitant medications, electrolyte 
abnormalities, and co-morbidities, all likely contributing to the 
low frequency of clinical cardiac toxicities reported post-
approval. Given the growing introduction of promising agents, 
designed to address unmet medical needs, efforts are needed 
to promote strategies for risk management, avoiding unintended 
consequences that can impede development, regulatory 
approval, and patient access. More research is needed to 
assess and manage cardiovascular safety of patients treated 
with anticancer agents, building from organized collaborations 
between oncologists and cardiologists, and these efforts should 
have broad relevance to therapeutics designed for treatment or 
supportive care. 
Risk–benefit assessments might be relatively straightforward in 
non-oncological studies and are provided in the ICH E14 
document. In principle, risk–benefit must be interpreted in the 
context of the nature and severity of the disease and 
conservative approaches will delay or prevent patient access to 
innovative treatment. Currently, different criteria are used in 
defining which prolongation of the QT-QTc time or change over 
baseline is feasible. The use of uniform thresholds to describe 
changes of concern for all protocol applications can simplify 
study conduct and subsequent data collection. Grading 
according to the Common Toxicities Adverse Events version 3 
(CTCAE v3) might be considered a uniform guideline in which 
grade 3 QT-QTc prolongation is defined as a value exceeding 
500 msec. In oncology trials, treatment related events of grade
3 or higher are often considered for decision making and dosing 
decisions. Asymptomatic prolongation of the QT-QTc time 
exceeding 60 msec over baseline may be too sensitive to guide 
dosing in oncological studies, since these changes can already 
be observed as a diurnal variation, even in healthy volunteers, 
and might even be larger in oncological patients. Of utmost 
importance is that the data generated in oncological studies are 
pooled to provide additional information on the QT/QTc interval 
in cancer patients and to guide us in broadening the eligibility 
criteria of studies in the oncologic setting, to implement the 
concomitant use of oncology relevant medication, to 
standardize dose-modification and discontinuation criteria, to 
search for alternatives in study design and result in timely 
approval of drugs by the regulatory authorities providing access 
for patients to promising new anti-cancer agents. 
 
Search strategy and selection criteria 
Material included in this review was identified from 
computerized searches of PubMed (1966 to September 2008), 
EMBASE (1974 to September 2008) and Current Contents 
(1998 to September 2008) using the medical subject headings 
(MeSH) terms ‘QTc prolongation or QT interval or arrhythmia, 
anticancer drugs. Free text terms ‘QTc prolongation* AND 
chemotherapy AND phase I’ were also used and combined with 
‘clinical trials’, ‘epidemiologic studies’, ‘animal studies’, and ‘in-
vitro studies’. Only peer-reviewed English-language papers 
were eligible for inclusion. Additional information and studies 
were obtained by checking the reference lists from retrieved 
papers. EMEA and FDA guidelines for QTc prolongation 
assessment were also considered in this review. 
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